Regencell Bioscience Holdings (RGC) Non-Current Assets (2020 - 2025)
Regencell Bioscience Holdings' (RGC) quarterly Non-Current Assets came in at $656170.0 in Q4 2025, down 23.05% on a QoQ basis from $852769.0 in Q2 2025.
Regencell Bioscience Holdings (RGC) Non-Current Assets (2020 - 2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 6 years of Non-Current Assets data on file, last reported at $656170.0 in Q4 2025.
- Quarterly Non-Current Assets changed N/A year-over-year to $656170.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $656170.0 (changed N/A YoY) and the FY2025 annual result came in at $852769.0, up 163.04% from the prior year.
- Non-Current Assets slipped to $656170.0 in Q4 2025, from $852769.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.6 million in Q2 2022 to a low of $273285.0 in Q2 2021.
- A 5-year average of $780192.7 and a median of $754469.5 in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 476.07% — and 2024, when it slumped 67.59%.
- Tracing RGC's Non-Current Assets over 5 years: stood at $273285.0 in 2021, then soared by 476.07% to $1.6 million in 2022, then slumped by 36.45% to $1.0 million in 2023, then tumbled by 67.59% to $324198.0 in 2024, then soared by 102.4% to $656170.0 in 2025.
- The last three Non-Current Assets figures came in at $656170.0 (Q4 2025), $852769.0 (Q2 2025), and $324198.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Regencell Bioscience Holdings | 2.67 Bn | 2.67 Bn | - | 656,170.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 656,170.00 |
| Jun 30, 2025 | 852,769.00 |
| Jun 30, 2024 | 324,198.00 |
| Jun 30, 2023 | 1.00 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Jun 30, 2021 | 273,285.00 |
| Jun 30, 2020 | 127,039.00 |